N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas.
Feng YuanYingshuai WangXiangming CaiChaonan DuJunhao ZhuChao TangJin YangChiyuan MaPublished in: Exploration of targeted anti-tumor therapy (2022)
A modification landscapes in LGGs. Moreover, this risk model may provide guidance and help in clinical prognosis assessment and immunotherapy response prediction for LGGs.
Keyphrases